SCHEMBL7944668

SCHEMBL7944668

Cc1c(C(=O)Nc2ccnc(C3(C)CC(=O)N(C)C(N)=N3)c2)oc2ccc(Cl)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 10/20 0.51
PKM P14618 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
RAB9A P51151 1/20 0.42
MAPT P10636 4/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
CLK1 P49759 1/20 0.41
GFER P55789 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
THRB P10828 1/20 0.39
APP P05067 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7939848 0.92 MAPT (0.45) BACE1RAB9AMAPTMEN1KMT2A
SCHEMBL7944683 0.91 BACE1 (0.44) BACE1RAB9AMAPTMEN1KMT2A
SCHEMBL7933355 0.91 BACE1 (0.49) BACE1RXFP1RAB9AMAPTPOLB
SCHEMBL7944678 0.91 RAB9A (0.47) BACE1RXFP1RAB9AMAPTMEN1
SCHEMBL7942114 0.90 LMNA (0.50) BACE1RXFP1RAB9AMAPTMEN1
SCHEMBL7933361 0.89 NPC1 (0.49) BACE1RXFP1RAB9AMAPTMEN1
SCHEMBL7939146 0.86 BACE1 (0.67) BACE1PKMRXFP1MAPTKDM4E
SCHEMBL7942669 0.86 BACE1 (0.54) BACE1PKMRXFP1PTGDR2
SCHEMBL7940948 0.85 BACE1 (0.53) BACE1L3MBTL1PTGDR2
SCHEMBL7939594 0.83 BACE1 (0.44) BACE1RAB9AMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885PKM 3320/4885RXFP1 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.